A collaborative project run by the Institute for Research in Biomedicine (IRB Barcelona) and Vall d’Hebron Institute of Oncology (VHIO) has received one of the funding concessions of the first call of the “Prova’t” programme, promoted by the “Generalitat de Catalunya” (Autonomous Government of Catalonia). “Prova’t” seeks to boost the transfer of results from research centres in Catalonia to the productive sector.
The project will develop a new therapeutic strategy for glioblastoma, a very aggressive type of brain cancer with poor prognosis. This research involves the work of scientists Meritxell Teixidó and Ernest Giralt, at IRB Barcelona, and Joan Seoane at VHIO.
“Prova’t” is promoted by the “Institució dels Centres de Recerca de Catalunya” (CERCA), an organisation affiliated to the Department of Economy and Knowledge, with the support of the Secretary for Universities and Research. In this first call, CERCA will assign a total of 1.5 million euros to seven research projects.